Single Biggest Cancer Dictionary in the World

What is anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing autologous T lymphocytes Hu1928-Hu20BB?

Pronunciation: /ˈænˌti ˈsiˈdi ˈnaɪnˈtin kɑr ˈsiˈdi twenty-eight* ˈsiˈdi tˈwɛnti kɑr fɔr wən bb* ɪkˈsprɛsɪŋ autologous* ti ˈlɪmfəˌsaɪts hu wən ˈθaʊzənd, naɪn ˈhənərd ənd twenty-eight* hu tˈwɛnti bb*/

anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing autologous T lymphocytes Hu1928-Hu20BB

Definition

A preparation of autologous human T lymphocytes that have been genetically modified to express the CAR construct Hu1928-Hu20BB that consists of two chimeric antigen receptor (CAR) constructs: one encoding a fully-human anti-CD19 CAR with a co-stimulatory domain of CD28, Hu19-CD828, and one encoding a human anti-CD20 CAR with a co-stimulatory domain of 4-1BB (CD137), Hu20BB, with potential immunostimulating and antineoplastic activities. Upon re-infusion, the anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing autologous T lymphocytes Hu1928-Hu20BB recognize and kill CD19- and/or CD20-expressing tumor B cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19- and/or CD20-expressing tumor cells, thereby causing tumor cell lysis. Both the tumor-associated antigens (TAAs) CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.